MX2023012489A - Polipeptido de fusion biespecifico multifuncional. - Google Patents
Polipeptido de fusion biespecifico multifuncional.Info
- Publication number
- MX2023012489A MX2023012489A MX2023012489A MX2023012489A MX2023012489A MX 2023012489 A MX2023012489 A MX 2023012489A MX 2023012489 A MX2023012489 A MX 2023012489A MX 2023012489 A MX2023012489 A MX 2023012489A MX 2023012489 A MX2023012489 A MX 2023012489A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- conjugate fragment
- fusion polypeptide
- terminus
- chain variable
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 230000004927 fusion Effects 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 abstract 8
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000003446 ligand Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente solicitud se refiere al campo técnico de la biomedicina y, en particular, a un polipéptido de fusión biespecífico. El polipéptido de fusión biespecífico comprende una fracción de unión a antígeno. La fracción de unión a antígeno comprende una primera fracción de unión a antígeno que comprende un Primer polipéptido que comprende un primer dominio variable de cadena pesada VH1 de un primer anticuerpo desde el extremo N hasta el extremo C, que está unido de forma operable a un primer fragmento conjugado; y un Segundo polipéptido que comprende un primer dominio variable de cadena ligera VL1 del primer anticuerpo desde la terminación N a la terminación C, que está unido operativamente a un segundo fragmento conjugado, en el que el primer fragmento conjugado y el segundo fragmento conjugado son capaces de unirse específicamente; y el primer fragmento conjugado es un receptor y el segundo fragmento conjugado es un ligando; o el primer fragmento conjugado es un ligando y el segundo fragmento conjugado es un receptor.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110436970 | 2021-04-22 | ||
CN202110871320 | 2021-07-30 | ||
CN202111121937 | 2021-09-24 | ||
CN202210240917 | 2022-03-10 | ||
PCT/CN2022/088198 WO2022223001A1 (zh) | 2021-04-22 | 2022-04-21 | 双特异性多功能融合多肽 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023012489A true MX2023012489A (es) | 2023-11-22 |
Family
ID=83723420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023012489A MX2023012489A (es) | 2021-04-22 | 2022-04-21 | Polipeptido de fusion biespecifico multifuncional. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4317184A1 (es) |
JP (1) | JP2024514802A (es) |
KR (1) | KR20230160389A (es) |
CN (1) | CN115925967A (es) |
AU (1) | AU2022261268A1 (es) |
BR (1) | BR112023021886A8 (es) |
CA (1) | CA3217520A1 (es) |
IL (1) | IL307899A (es) |
MX (1) | MX2023012489A (es) |
TW (1) | TW202241968A (es) |
WO (1) | WO2022223001A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022105872A1 (zh) * | 2020-11-23 | 2022-05-27 | 广东菲鹏制药股份有限公司 | 抗tigit抗体或其抗原结合片段 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
JP4603894B2 (ja) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | 抗体産生細胞を同定するためのアッセイ |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
PL3587448T3 (pl) | 2013-03-15 | 2021-11-29 | Xencor, Inc. | Białka heterodimeryczne |
CA2935599A1 (en) * | 2014-01-08 | 2015-07-16 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Il-15 heterodimeric protein and uses thereof |
SI3235830T1 (sl) * | 2014-12-19 | 2020-12-31 | Jiangsu Hengrui Medicine Co., Ltd. | Proteinski kompleks interlevkina 15 in njegove uporabe |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
KR102463844B1 (ko) * | 2016-05-27 | 2022-11-08 | 알토 바이오사이언스 코포레이션 | Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명 |
MX2020003145A (es) * | 2017-09-22 | 2020-07-29 | Wuxi Biologics Ireland Ltd | Nuevos complejos de polipeptidos biespecificos. |
CA3097649A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
AU2019256539A1 (en) * | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
-
2022
- 2022-04-21 KR KR1020237036723A patent/KR20230160389A/ko active Search and Examination
- 2022-04-21 EP EP22791107.0A patent/EP4317184A1/en active Pending
- 2022-04-21 JP JP2023561150A patent/JP2024514802A/ja active Pending
- 2022-04-21 AU AU2022261268A patent/AU2022261268A1/en active Pending
- 2022-04-21 WO PCT/CN2022/088198 patent/WO2022223001A1/zh active Application Filing
- 2022-04-21 CN CN202210422982.8A patent/CN115925967A/zh active Pending
- 2022-04-21 MX MX2023012489A patent/MX2023012489A/es unknown
- 2022-04-21 CA CA3217520A patent/CA3217520A1/en active Pending
- 2022-04-21 BR BR112023021886A patent/BR112023021886A8/pt unknown
- 2022-04-21 IL IL307899A patent/IL307899A/en unknown
- 2022-04-21 TW TW111115310A patent/TW202241968A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW202241968A (zh) | 2022-11-01 |
BR112023021886A2 (pt) | 2023-12-19 |
CA3217520A1 (en) | 2022-10-27 |
EP4317184A1 (en) | 2024-02-07 |
IL307899A (en) | 2023-12-01 |
CN115925967A (zh) | 2023-04-07 |
JP2024514802A (ja) | 2024-04-03 |
AU2022261268A1 (en) | 2023-11-16 |
WO2022223001A1 (zh) | 2022-10-27 |
KR20230160389A (ko) | 2023-11-23 |
BR112023021886A8 (pt) | 2024-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4249068A3 (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
MX2020002880A (es) | Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). | |
PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
EA202092844A1 (ru) | Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применение | |
WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
CY1118709T1 (el) | Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf | |
AU2010234031A8 (en) | Trivalent, bispecific antibodies | |
JP2017504578A5 (es) | ||
NZ730933A (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
WO2006071441A3 (en) | Antibodies directed to gpnmb and uses thereof | |
RU2016138347A (ru) | Трифункциональная антигенсвязывающая молекула | |
RU2011148913A (ru) | Иммуноглобулин с двумя вариабельными доменами и его применение | |
EA201290568A1 (ru) | Связывающие гетеродимер протеины и их применение | |
JP2014519322A5 (es) | ||
NZ588713A (en) | Antibodies to receptor of advanced glycation end products (rage) and uses thereof | |
NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
ECSP099683A (es) | Proteinas de union incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos que se unen especificamente a cd154 y sus usos. | |
PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
MX2022007636A (es) | Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica. | |
PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
MX2023012489A (es) | Polipeptido de fusion biespecifico multifuncional. | |
MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
PE20230856A1 (es) | Proteinas de union restringidas activadas de forma condicional | |
WO2011064257A3 (de) | Monospezifische polypeptidreagenzien | |
PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos |